The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
From the 23rd of March.
NDD has successfully been used to target host-virus biology in influenza A without affecting host cell viability
• We aim to apply the same strategy to COVID-19
• We are collecting and processing COVID-19/host interaction data needed for the analyses
• We intend to have compounds to test within 3 months
Are we getting close to testing?
https://www.etherapeutics.co.uk/media/1237/covid-19_ndd_overview.pdf
Let’s face it, if anyone is going to crack covid, ETX has a better chance than most.
Just to make a note, Logitech Made 2.8 billion revenue last year.
Or news is about to drop. Don’t forget, no debt and funded.
Few 50k trades going through. Someone building a stake.
Maybe buying etx, some buying going on this morning.
Err what’s with all the sells after hours? Few million quids worth.....
Not to drag over old coals but tw is border line obsessive with all this, opinion is one thing but when you start publishing peoples names and addresses then making threats. Tut,tut.
Won’t post the link as I don’t like promoting the site.
Cretinous IT programmer Mike Turner of Whitney Close, Raunds, Northants – your problems are only beginning
Now that will be the demise of tw, he leaves a paper trail so long of all comments published it’s not just a shorting tip. It’s personal.
Googling etherapeutics and refining the search to over last few months, there are quiet a few reports out and market expectations for different projects which ET are involved in. We are up there with some major players.
For eg.
The major players covered in Major Depressive Disorder Therapeutic are:
Pfizer
Naurex
Otsuka Pharmaceutical
Eli Lilly
Takeda Pharmaceutical
H. Lundbeck
E-therapeutics
Alkermes
AstraZeneca
Euthymics Bioscience
This is just one of a few.
Big time.
When it gets through 13p.... Stubborn sod init.
Also, confidently showing the bird to the obsessed clowns who spend everyday repeating the same old kak.
What’s with aim today, loads in the red.
Thinking that , just looked at the rns from March 23rd. 6 weeks and some progress should of been made.
We have the capability to carry out such in silico screening in a matter of weeks and indeed have already begun this process. However, in order to test the outputs in appropriate cellular systems as quickly as possible, we would require the help of established partners with relevant assays for Sars-CoV-2. We would also need help with additional experimental work (e.g. proteomic studies) that might enhance this project with additional data.
We have therefore begun business development efforts across the pharmaceutical industry to gauge interest in making such capacity available collaboratively for the greater good. We would ask that any potential partner reading this release, whether industrial, governmental or academic, that has complementary resource and expertise to make contact with us to explore ways in which we can progress.
Bit of demand for the shares by the looks. Just wait and see if the covid herd get a sniff, anything slightly lab based is going through the roof atm.
Must say I, and probably most of you, just skimmed through that report and picked out bits. You actually need to read it properly and take in the new tech, platforms, research, partners, accreditation, and work which is going into all of this. It’s impressive. We’re already almost halfway through this year, progression will be fast from here on in.
While we are working hard to increase the breadth of our inventory of games in H1 2020 and with some success, the board continues to expect that revenues in H1 2020, although higher than total revenues for 2019, will continue to be minor and that material revenues for 2020 will start to occur only in the second half,'
So without giving the game away, they’re positive they are going to make more than 500k in the first half, ‘we’re in May already.’ Then from the second half, July onwards ‘New contracts must kick in’
Good read on the technical analysis and charts for bids on Friday. Updated to a buy from hold.
https://stockinvest.us/technical-analysis/BIDS.L
Just the pop up ads are abit of a pain.